News

Weight loss jabs will be given to 3,000 people in a trial to explore whether they can get people back into work, The i Paper ...
The rise of GLP-1 drugs is a reminder that we must move beyond the simple equation of thinness as health and value. These ...
So much information surrounds weight-loss jabs and so understanding what to expect from them can feel daunting ...
Overview of Obesity Treatment MarketThe global Obesity Treatment Market is valued at USD 22.2 Billion in 2024 and is projected to reach a value of USD 194.1 Billion by 2035 at a CAGR (Compound Annual ...
Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...
Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.
Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type ...
A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with overweight or obesity, outperforming liraglutide and placebo. Brain ...
Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body weight, food intake and many measures of appetite more than placebo and ...
A new study reports that people taking GLP-1 drugs in daily life don’t lose as much weight as those in clinical trials who take the same medications. One possible reason for the weight loss ...
By Hugo Francisco de Souza A new clinical trial reveals tirzepatide’s ability to curb hunger and alter brain responses to food, marking a new era in obesity treatment. Study: Tirzepatide on ...